Dissemin is shutting down on January 1st, 2025

Published in

MDPI, Current Oncology, 5(29), p. 3647-3657, 2022

DOI: 10.3390/curroncol29050293

Links

Tools

Export citation

Search in Google Scholar

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Journal article published in 2022 by Zeljko Todorovic ORCID, Dusan Todorovic, Vladimir Markovic, Nevena Ladjevac, Natasa Zdravkovic, Predrag Djurdjevic, Nebojsa Arsenijevic, Marija Milovanovic, Aleksandar Arsenijevic ORCID, Jelena Milovanovic
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.